Sentence examples for modifying agents to from inspiring English sources

Ionic liquids (ILs) have recently been proposed as modifying agents to tune the selectivity and the activity of electrocatalysts.

The dispersion of TiO2 nanoparticles in the mineral oil can also be improved by adjusting the usage of modifying agents to functionalize the nanoparticles [18].

In this paper, the recovered waste packaging ethylene-vinyl acetate copolymer (EVA) and crumb rubber (CR) were used as polymer modifying agents to prepare EVA/CR modified asphalt, and the EVA/CR modified asphalt's dynamic stability were studied.

The addition of histone modifying agents to RTK inhibitors may thus be of therapeutic benefit in this group of patients.

We expected less trapping of basic drugs in endosomes with raised pH and confirmed that there was direct correlation between the ability of modifying agents to raise endosomal pH and to reduce doxorubicin fluorescence in endosomes.

For example, inflammatory arthritis (such as RA, ankylosing spondylitis, psoriatic arthritis, juvenile idiopathic arthritis/JRA) requires early referral to speciality rheumatology clinics and early intervention with disease modifying agents to minimise the burden of pain and disability.

The challenges in finding a suitable surface modifying agent to overcome the hydrophobicity of the as-synthesized iron oxide nanoparticles were met out.

Sulfonated poly (ether-ether-ketone) (SPEEK) was selected as a surface modifying agent to prepare non-covalently functionalized reduced graphene oxide (NFrGO) followed by the development of NFrGO/cellulose acetate (CA) nanocomposite (NFrGO-CANC) through solution mixing.

Moreover, even phase II studies with more optimal disease modifying agents fail to show evidence for significant efficacy.

15 16 If more then one time point was reported we extracted the latest time point up to three months after the end of treatment for potentially structure modifying agents and up to 12 months after the end of treatment for behaviour changing interventions.

We have established recently a method of quantifying tissue gradients of doxorubicin from blood vessels in solid tumours (Primeau et al, 2005), and will investigate the use of modifying agents studied here to change those distributions in tumours.